Date amended:
External
Repatriation Medical Authority Statement

Gastro-oesophageal reflux disease - Treatment with a smooth muscle relaxant drug Factor

In the SOP for gastro-oesophageal reflux disease the Repatriation Medical Authority defines a smooth muscle relaxant drug as “an anti-cholinergic drug, a beta-adrenergic drug, a nitrate drug, a calcium channel blocker drug, theophylline or aminophylline”.  Information about these drugs is contained in the hotwords below:

  • Aminophylline
  • Anti-cholinergic drugs
  • Beta-adrenergic drugs are also known as beta blockers
  • Calcium channel blockers
  • Nitrates
  • Theophylline

A history of ingestion of a drug may be documented in the medical evidence.  However, if these cannot be obtained, a statement that a particular drug was taken at a particular time will generally be accepted, unless there is contradictory evidence.  Seek medical advice if it is unclear whether the claimed treatment with the drug is medically feasible.

Last reviewed for CCPS 18 July 2005.

Investigative Documents
Type Title PDF Format Word Format
Medical Report
Smooth Muscle Relaxant Drugs - Gastro-Oesophageal Reflux Disease
Document
Document
Preliminary questions [6483]

29294 there is some evidence that treatment with a smooth muscle relaxant drug may be a factor in the development or worsening of the condition under consideration.

6523     the veteran was being treated with a smooth muscle relaxant drug for an illness or injury which is identifiable.

29295 the identified illness or injury, for which the veteran was being treated with a smooth muscle relaxant drug, is a condition for which the drug cannot be ceased or substituted.

6524     the veteran has established the causal connection between the treatment with the smooth muscle relaxant drug and VEA service for gastro-oesophageal reflux disease.

6527     for the identified illness or injury, the veteran was being treated with a smooth muscle relaxant drug, which could not be ceased or substituted, at the time of the clinical onset of the condition under consideration.

6525     the veteran has established the causal connection between the treatment with the smooth muscle relaxant drug and VEA service for the clinical onset of gastro-oesophageal reflux disease.

6529     the veteran has established the causal connection between the treatment with the smooth muscle relaxant drug and operational service for the clinical onset of gastro-oesophageal reflux disease.Ê

or

6530     the veteran has established the causal connection between the treatment with the smooth muscle relaxant drug and eligible service for the clinical onset of gastro-oesophageal reflux disease.

or

7334     the clinical onset of the condition under consideration occurred after the end of the veteran's last period of VEA service.

7335     the condition under consideration permanently worsened.

6528     for the identified illness or injury, the veteran was being treated with a smooth muscle relaxant drug, which could not be ceased or substituted, at the time of the clinical worsening of the condition under consideration.

6526     the veteran has established the causal connection between the treatment with the smooth muscle relaxant drug and VEA service for the clinical worsening of gastro-oesophageal reflux disease.

6531     the veteran has established the causal connection between the treatment with the smooth muscle relaxant drug and operational service for the clinical worsening of gastro-oesophageal reflux disease.

or

6532     the veteran has established the causal connection between the treatment with the smooth muscle relaxant drug and eligible service for the clinical worsening of gastro-oesophageal reflux disease.

Clinical onset and operational service [6529]

6534     the identified illness or injury which required treatment with the smooth muscle relaxant drug is causally related to operational service.

Clinical onset and eligible service [6530]

6535     the identified illness or injury which required treatment with the smooth muscle relaxant drug is causally related to eligible service.

Clinical worsening and operational service [6531]

6534     the identified illness or injury which required treatment with the smooth muscle relaxant drug is causally related to operational service.

6537     the clinical onset of the condition under consideration occurred prior to that part of operational service to which the identified illness or injury which required treatment with the smooth muscle relaxant drug is causally related.

Clinical worsening and eligible service [6532]

6535     the identified illness or injury which required treatment with the smooth muscle relaxant drug is causally related to eligible service.

6538     the clinical onset of the condition under consideration occurred prior to that part of eligible service to which the identified illness or injury which required treatment with the smooth muscle relaxant drug is causally related.